Prior Movesmirror the world’s best investors

What is SPARX Asset Management buying in Japan next?

SPARX Asset Management (JP) discloses its Japanese stakes under Japan’s own regime, EDINET large-shareholding reports (大量保有報告書), the side a US 13F is blind to. Japan is also the one market where a prediction is checkable almost immediately: the report is due within about five business days of crossing 5%, not the US 13F’s 45. Research, not investment advice.

VERIFIABLE IN ~5 BUSINESS DAYSpredicted now · confirmed when the 大量保有 files

Predicted next buys

P(this fund adds the name next), from the per-investor walk-forward model, out-of-sample AUC ~83%. A predicted probability is a statement about a filing pattern, never a claim the fund has bought a name or that you should.

CompanyP(add next)StakeSignalNext filing due
前田工繊株式会社 (7821)32%7.2%holder2026-08-10
株式会社SHOEI (7839)19%11.0%holder2026-07-21

Currently disclosed Japanese holdings

From SPARX Asset Management’s latest EDINET 5% filings. Stake is the disclosed large-shareholding percentage.

IssuerStakePurposeAs of
株式会社JDSC (4418)13.7%institutional2021-12-23
株式会社SHOEI (7839)11.0%institutional2026-05-28
株式会社LITALICO (7366)8.0%institutional2026-04-02
前田工繊株式会社 (7821)7.2%institutional2026-06-17
株式会社マネジメントソリューションズ (7033)6.4%institutional2026-01-06
フロンティア・マネジメント株式会社 (7038)5.2%institutional2021-03-17
サスメド株式会社 (4263)5.2%institutional2025-01-07
日精エー・エス・ビー機械株式会社 (6284)5.1%institutional2023-02-02
株式会社ヒット (378A)5.1%institutional2026-01-06
月島機械株式会社 (6332)5.0%institutional2022-12-15
トーセイ株式会社 (8923)5.0%institutional2023-02-17
株式会社ギフト (9279)5.0%institutional2022-01-31
神戸天然物化学株式会社 (6568)5.0%institutional2021-11-02
ロート製薬株式会社 (4527)5.0%institutional2023-02-17
株式会社I-ne (4933)4.7%institutional2025-11-19
The weekly digest

The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.

The full Japan board, predicted and disclosed, is on Japan. How the model works and its honest limits are on methodology. Data as of 2021-12-23. Research, not investment advice, see the disclaimer.